Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MERS-CoV recombinant vaccine
- Development stage
- Preclinical
- Lead developer
- Techinvention Lifecare
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MERS-CoV recombinant vaccine is a protein subunit vaccine candidate being developed by Techinvention Lifecare for the prevention of Middle East Respiratory Syndrome (MERS). The vaccine utilizes recombinant protein technology to express key antigens of the MERS-CoV virus, such as the spike protein or its receptor-binding domain, to stimulate the production of neutralizing antibodies and cellular immune responses. It is currently in the preclinical (R&D) stage of development as part of the company's portfolio targeting emerging infectious diseases and "One Health" initiatives.
- Other names
- MERS-CoV recombinant protein vaccine
02
Targets
MERS-CoV S (MERS-CoV spike glycoprotein)SARS-CoV-2 spike
Beyond the preview
Go deeper on MERS-CoV recombinant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MERS-CoV recombinant vaccine.